Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.5, expectations were $1.38. Operator: Good afternoon. And welcome to the ...

6. Elevidys for Duchenne muscular dystrophy (DMD) On June 20, 2024, the FDA expanded the approval of Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy initially ...

Sarepta Therapeutics, Inc. SRPT reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of $1.87. However, the reported figure was significantly ...

In June of last year, ELEVIDYS as you know had an expansion of their label. So that allowed for boys four years of age and older, regardless of ambulatory status, to be eligible or considered for ...

Douglas Ingram; President, Chief Executive Officer, Director; Sarepta Therapeutics Inc Dallan Murray; Executive Vice President, Chief Customer Officer; Sarepta Therapeutics Inc Louise Rodino-Klapac; ...

Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over the same quarter of the prior year – ELEVIDYS net product revenue for the quarter totaled $384.2 million; ...

Net product revenues soared 75% to $638.2 million compared to the same quarter last year, driven by strong sales of its gene therapy ELEVIDYS. ELEVIDYS, approved in June 2023 for Duchenne muscular ...

Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over the same quarter of the prior year – ELEVIDYS net product revenue for the quarter totaled $384.2 ...

We also see benefits from Xolair food allergy and upside from Elevidys. Our numbers show at least $16 billion in sales potential from late-stage pipeline success. In 2025 (Fig 5), we are carefully ...